Trial · NCT03400163
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | BMS-986036 20 mg QD | NA | 90% Confidence Interval NA to NA | percentage | |
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | Placebo 20 mg QD | NA | 90% Confidence Interval NA to NA | percentage | |
| Number of Participants With Adverse Events (AEs) | BMS-986036 20 mg QD | NA | Participants | ||
| Number of Participants With Adverse Events (AEs) | Placebo 20 mg QD | NA | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | BMS-986036 20 mg QD | NA | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | Placebo 20 mg QD | NA | Participants | ||
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QD | Injection Site Bruising | NA | Participants | |
| Number of Participants With Injection Site Reactions | Placebo 20 mg QD | Injection Site Bruising | NA | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QD | Injection Site Erythema | NA | Participants | |
| Number of Participants With Injection Site Reactions | Placebo 20 mg QD | Injection Site Erythema | NA | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QD | Injection Site Reaction | NA | Participants | |
| Number of Participants With Injection Site Reactions | Placebo 20 mg QD | Injection Site Reaction | NA | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QD | Injection Site Pain | NA | Participants | |
| Number of Participants With Injection Site Reactions | Placebo 20 mg QD | Injection Site Pain | NA | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QD | Injection Site Rash | NA | Participants | |
| Number of Participants With Injection Site Reactions | Placebo 20 mg QD | Injection Site Rash | NA | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QD | Injection Site Swelling | NA | Participants | |
| Number of Participants With Injection Site Reactions | Placebo 20 mg QD | Injection Site Swelling | NA | Participants | |
| Number of Participants With Adverse Events Leading to Discontinuation | BMS-986036 20 mg QD | NA | Participants | ||
| Number of Participants With Adverse Events Leading to Discontinuation | Placebo 20 mg QD | NA | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03400163/results